Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × UNKNOWN × anlotinib × Clear all

Phase

Status

Unknown 5 Completed 1

Sponsor Class

OTHER 19 INDUSTRY 10 UNKNOWN 1 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

S 1 (combination) 7 Cisplatin 6 Radiotherapy, Intensity-Modulated 5 Paclitaxel 4 Oxaliplatin 3 Irinotecan 3 titanium silicide 2 raltitrexed 2 nimotuzumab 2 Radiotherapy 2 Radiation Dose Hypofractionation 2 Capecitabine 2 pegylated granulocyte colony-stimulating factor 1 nabiximols 1 icaritin 1 gimeracil 1 anlotinib 1 Trastuzumab 1 Temozolomide 1 Tegafur 1 TP protocol 1 Surgical Procedures, Operative 1 Radiotherapy, Adjuvant 1 Radiation 1 Pharmaceutical Preparations 1 Ondansetron 1 Methylene Blue 1 Lidocaine 1 Injections 1 Indocyanine Green 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04002284 2020-07-29

Anlotinib in Metastatic HER2 Negative Breast Cancer

ChineseAMS

Phase 2 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡